|
Inovio Pharmaceuticals Inc (NASDAQ: INO) |
|
Inovio Pharmaceuticals Inc
INO's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Inovio Pharmaceuticals Inc 's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Inovio Pharmaceuticals Inc net loss decreased from $-34 millions, to $-25 millions in III. Quarter 2024,
• More on INO's Growth
|
|
Inovio Pharmaceuticals Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 21.28 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 12.7.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.
• More on INO's Valuation
|
|
|
|
|
Inovio Pharmaceuticals Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 21.28 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 12.7.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.
Inovio Pharmaceuticals Inc Price to Book Ratio is at 0.83 lower than Industry Avg. of 69.01. and higher than S&P 500 Avg. of 0.01
• More on INO's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com